AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02248844 — intervention group
Intervention type: BIOLOGICAL
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
Study NCT01310842 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
Study NCT01310842 — intervention group
Intervention type: DRUG
Intervention: Nicotine Patch Therapy
Description: 4 weeks of nicotine patch therapy
Study NCT01310842 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling Sessions
Description: 5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
Study NCT00372684 — intervention group
Intervention type: GENETIC
Intervention: with severe malaria hospitalized in ICU
Description: with severe malaria hospitalized in ICU
Study NCT00372684 — intervention group
Intervention type: GENETIC
Intervention: with uncomplicated malaria
Description: with uncomplicated malaria
Study NCT00669669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal IMRT
Study NCT00669669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Study NCT00669669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT00669669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00669669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplant
Study NCT00669669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo 3D conformal IMRT
Study NCT00669669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00669669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: Given IV
Study NCT00669669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT00669669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT00669669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT00860795 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
Study NCT00860795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 25 ml daily in 2 divided doses for 10 days
Study NCT03452670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Group
Description: Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
Study NCT03452670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Group
Description: The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
Study NCT02242812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02242812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Study NCT02242812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02242812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01238172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary education and counseling
Study NCT01238172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prostate cancer foundation booklet
Study NCT01387672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates (NABT Main trial)
Description: nitroglycerin; isosorbide mononitrate
Study NCT01387672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment
Study NCT02790372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case conferencing
Description: Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
Study NCT01339468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT01339468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT01339468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: intravenous
Study NCT01339468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: intravenous
Study NCT02487368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle stimulation pad
Study NCT03088280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: reduced dose (3mg/Kg)
Study NCT03088280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: reduced dose (3mg/Kg)
Study NCT00038467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Study NCT00038467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Study NCT00996008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 g (w/w) placebo cream applied to each target lesion twice daily
Study NCT00996008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT 327
Description: 0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
Study NCT06541925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection with the needle-free (NF) system
Description: Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
Study NCT06541925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Injection with the traditional method (TM)
Description: The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
Study NCT02467972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat frozen soups added unripe banana flour
Description: Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
Study NCT02467972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready-to-eat frozen soups added maltodextrin
Description: Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
Study NCT02467972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat frozen soups added inulin
Description: Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
Study NCT02467972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat frozen soups added nisin
Description: Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
Study NCT03962218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aquatic physiotherapy
Description: specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
Study NCT03962218 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: aquatic physiotherapy
Description: specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
Study NCT03296215 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: To determine different patterns of admission and their Outcome
Study NCT04101721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Administered IVT
Study NCT04101721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: Transpupillary conventional laser will be administered according to standard local procedures.
Study NCT03956901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pvi guided fluid management
Description: GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13.
Study NCT02531698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 Vaccine
Description: 1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
Study NCT02531698 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Licensed pediatric hepatits A vaccine
Description: 1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
Study NCT02531698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
Study NCT01164137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation
Description: A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
Study NCT04218344 — intervention group
Intervention type: OTHER
Intervention: 60mls of blood donated for research analysis
Description: All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
Study NCT02255773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Tasks
Description: 3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
Study NCT00799812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).
Description: 3 swabsticks topically applied at the same time to intact skin
Study NCT00799812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG 2% w/v & IPA 70% v/v swab applied sequentially
Description: Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
Study NCT00799812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous CHG 4% w/v applied according to mfr's directions
Description: Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
Study NCT00799812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile swabstick with sterile water (3 @ once)
Description: 3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
Study NCT00799812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile swabstick with sterile water (one-at-a-time)
Description: Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
Study NCT02154516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ODH Hip System
Study NCT02154516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODH Hip System
Study NCT01515202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, Once daily, 14 days
Study NCT02255773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
Study NCT01515202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 12 mg, Once daily, 14 days
Study NCT01515202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 25 mg, Once daily, 14 days
Study NCT01515202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 15 mg, Once daily, 14 days
Study NCT01515202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 14 days
Study NCT00308113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0/75 mg/kg/day.
Study NCT01713478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
Study NCT00308113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: serum levels of greater or equal to 2.5 micrograms/mL.
Study NCT01713478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography
Description: The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
Study NCT03071341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
Study NCT05308342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of human UC-MSCs into ovaries of POI patients
Description: UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
Study NCT05308342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormone replacement treatment
Description: Routine estrogen progesterone replacement periodic therapy
Study NCT05308342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormone replacement treatment
Description: Routine estrogen progesterone replacement periodic therapy
Study NCT00377195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Field Radiotherapy
Description: The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days.
Study NCT03396783 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: during the visit, nurse will make a blood test for biological and immunological analysis
Study NCT03396783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: during the visit, nurse will make a blood test for biological and immunological analysis
Study NCT03396783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromyogram and walk test
Description: during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
Study NCT02809495 — intervention group
Intervention type: OTHER
Intervention: use of app in smartphone
Study NCT03286426 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pictor
Description: The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
Study NCT03208387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion tensor imaging (DTI)
Description: DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
Study NCT01170767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
Study NCT01170767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
Study NCT01518465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Description: Given SC
Study NCT01518465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT01518465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT01518465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03369314 — intervention group
Intervention type: DRUG
Intervention: octaplasLG®
Description: Data will be collected in all patients who have received at least one infusion of octaplasLG®
Study NCT03208387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Resting state functional connectivity MRI (rs-fcMRI)
Description: rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
Study NCT03208387 — intervention group
Intervention type: BEHAVIORAL
Intervention: Wechsler Intelligence Scale for Children - 5th edition (WISC-V)
Description: Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
Study NCT03208387 — intervention group
Intervention type: BEHAVIORAL
Intervention: California Verbal Learning Test (CVLT-C)
Description: Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.